MorphoSys (NASDAQ:MOR) Sets New 52-Week Low at $12.50

MorphoSys AG (NASDAQ:MOR)’s share price reached a new 52-week low on Monday . The company traded as low as $12.50 and last traded at $12.50, with a volume of 2450 shares trading hands. The stock had previously closed at $12.89.

A number of analysts have weighed in on MOR shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of MorphoSys in a research note on Wednesday, August 4th. Deutsche Bank Aktiengesellschaft lowered MorphoSys from a “buy” rating to a “hold” rating in a report on Thursday, August 5th. Morgan Stanley reissued an “overweight” rating on shares of MorphoSys in a report on Wednesday, August 4th. Commerzbank lowered MorphoSys from a “buy” rating to a “hold” rating and set a $59.00 price target on the stock. in a report on Tuesday, July 27th. Finally, Landesbank Baden-Wuerttemberg lowered MorphoSys from a “buy” rating to a “hold” rating in a report on Wednesday, June 16th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $23.72.

The company’s 50 day moving average price is $14.77 and its 200-day moving average price is $19.37. The company has a market capitalization of $1.69 billion, a PE ratio of -13.24 and a beta of 0.94. The company has a current ratio of 6.14, a quick ratio of 6.07 and a debt-to-equity ratio of 0.46.

MorphoSys (NASDAQ:MOR) last announced its quarterly earnings data on Wednesday, July 28th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.66. MorphoSys had a negative net margin of 68.05% and a negative return on equity of 16.50%. The company had revenue of $46.06 million during the quarter, compared to analysts’ expectations of $46.02 million. As a group, analysts predict that MorphoSys AG will post -1.78 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in MOR. BlackRock Inc. lifted its holdings in MorphoSys by 23,165.7% in the 2nd quarter. BlackRock Inc. now owns 773,817 shares of the company’s stock worth $14,896,000 after buying an additional 770,491 shares in the last quarter. Millennium Management LLC lifted its holdings in MorphoSys by 73.6% in the 2nd quarter. Millennium Management LLC now owns 326,631 shares of the company’s stock worth $6,288,000 after buying an additional 138,433 shares in the last quarter. Optiver Holding B.V. acquired a new position in MorphoSys in the 1st quarter worth $3,064,000. Eqis Capital Management Inc. acquired a new position in MorphoSys in the 1st quarter worth $963,000. Finally, OLD Mission Capital LLC acquired a new position in MorphoSys in the 2nd quarter worth $704,000. 1.71% of the stock is owned by hedge funds and other institutional investors.

MorphoSys Company Profile (NASDAQ:MOR)

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry.

See Also: Investing in Growth Stocks

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.